Antithrombin III activity, von Willebrand factor antigen and platelet function in young diabetic patients treated with multiple insulin injections versus insulin pump treatment

European Journal of Clinical Investigation
S E HustedH Beck-Nielsen

Abstract

In a prospective study with cross-over design 20 patients with insulin-dependent diabetes mellitus of more than 2 years duration were treated for 6 months with continuous subcutaneous insulin infusion (CSII) and multiple insulin injections (MII). Metabolic control, platelet aggregability, thromboxane B2 levels in serum and plasma as well as antithrombin III (ATIII) activity and von Willebrand factor antigen were evaluated. A good metabolic control was obtained by both intensified regimens. No difference could be demonstrated between either platelet function tests or serum level of von Willebrand factor antigen during treatment with CSII and MII. However, the plasma level of ATIII activity was significantly higher (P less than 0.01) during MII treatment as compared to CSII treatment. There was no correlation between ATIII activity and daily insulin requirement or serum fructosamine. In conclusion, long-term metabolic control with MII has a favourable effect on ATIII activity in plasma. This may be important for a delay in onset and progression of diabetic vascular complications.

References

Jan 28, 1978·British Medical Journal·J C PickupK G Alberti
Apr 1, 1977·Annals of Internal Medicine·C M PetersonM L Lehrman
Nov 30, 1983·The American Journal of Medicine·J A ColwellP V Halushka
Sep 6, 1984·The New England Journal of Medicine·J F Mustand, M A Packham
May 1, 1984·Scandinavian Journal of Clinical and Laboratory Investigation·H K NielsenS E Husted
Jan 7, 1983·Clinica Chimica Acta; International Journal of Clinical Chemistry·R N JohnsonJ R Baker
Feb 1, 1981·The American Journal of Medicine·R L Jones, C M Peterson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.